Clinical Trial

Dalbavancin Therapy for Infective Endocarditis

Study acronym: EndoDalba
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study compares two treatment strategies for antibiotic therapy in endocarditis. The aim of the study is to determine which treatment is more effective overall and better tolerated by patients. The first strategy is standard therapy: treatment with proven antibiotics, which are usually administered initially as an intravenous infusion in the hospital and can be switched to oral therapy with tablets later on for suitable patients. The second strategy is the study treatment with dalbavancin: This is a long-acting antibiotic. It is administered as a single infusion; for longer treatment durations, a second infusion may be necessary 14 days later.
Trial Details
NCT Number NCT07699211
Lead Sponsor Stefan Hagel
Conditions Endocarditis Infective, Endocarditis, Bacterial
Enrollment 184 participants
Start Date 2026-12
Primary Completion 2028-09 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-13